欧洲转移性黑色素瘤新疗法可及性的最新进展——2024年欧洲黑色素瘤登记处和欧洲皮肤肿瘤协会的一项调查。

IF 7.6 1区医学 Q1 ONCOLOGY

European Journal of Cancer Pub Date : 2025-02-05 DOI:10.1016/j.ejca.2024.115124

L. Kandolf , P.A. Ascierto , L. Bastholt , I. Gavrilova , J. Haanen , A. Hauschild , D. Herceg , C. Hoeller , A. Jalovcic Suljevic , JI Kessels , I. Krajsova , M. Kukushkina , A. Lallas , P. Lorigan , J. Mangana , I. Marquez-Rodas , L. Mazilu , P. Mohr , M. Bylaite-Bucinskiene , J. Ocvirk , C. Garbe

{"title":"欧洲转移性黑色素瘤新疗法可及性的最新进展——2024年欧洲黑色素瘤登记处和欧洲皮肤肿瘤协会的一项调查。","authors":"L. Kandolf , P.A. Ascierto , L. Bastholt , I. Gavrilova , J. Haanen , A. Hauschild , D. Herceg , C. Hoeller , A. Jalovcic Suljevic , JI Kessels , I. Krajsova , M. Kukushkina , A. Lallas , P. Lorigan , J. Mangana , I. Marquez-Rodas , L. Mazilu , P. Mohr , M. Bylaite-Bucinskiene , J. Ocvirk , C. Garbe","doi":"10.1016/j.ejca.2024.115124","DOIUrl":null,"url":null,"abstract":"<div><div>Advances in cancer treatments have significantly improved their effectiveness, yet access to first-line therapies remains limited. A 2017 survey revealed that over 25 % of metastatic melanoma patients in Europe lacked access to recommended therapies. To address this, the European Association of Dermato-Oncology and the European Melanoma Registry conducted a follow-up study on the registration and reimbursement of first-line treatments.A web-based survey using LimeSurvey was distributed to melanoma experts across 27 European countries from February to April 2022 and updated from February to April 2024. The questionnaire covered the percentage of patients receiving recommended treatments, as well as treatment authorization and reimbursement dates for systemic and adjuvant therapies.There has been significant improvement in the registration and reimbursement of BRAFi/MEKi, anti-PD1, and anti-PD1/anti-CTLA4 therapies, increasing from 48 %, 63 %, and 37 % in 2017 to 96 %, 96 %, and 78 % in 2024, respectively. Despite these gains, restrictions persist. Anti-PD1/anti-CTLA4 combination immunotherapy is still not available without restrictions in 48 % of the surveyed countries. The nivolumab/relatlimab combination is licensed only for PDL-1-negative melanoma and reimbursed in seven countries of Europe. Tebentafusp is reimbursed in 15 countries and talimogene laherpervec in 5. In 2024, adjuvant treatments for stage III melanoma are reimbursed in 22 countries for dabrafenib/trametinib and 24 of 27 for anti-PD1 antibodies. Pembrolizumab and nivolumab are reimbursed in 15 and 8 countries, respectively, for stage IIB/IIC disease.While there have been improvements in the reimbursement of metastatic melanoma treatments in Europe, challenges and discrepancies remain. Further efforts at European and global levels are needed to harmonize and enhance access to cancer medicines.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"216 ","pages":"Article 115124"},"PeriodicalIF":7.6000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"An update on access to novel treatment for metastatic melanoma in Europe — A 2024 survey of the European melanoma registry and the European association of dermato-oncology\",\"authors\":\"L. Kandolf , P.A. Ascierto , L. Bastholt , I. Gavrilova , J. Haanen , A. Hauschild , D. Herceg , C. Hoeller , A. Jalovcic Suljevic , JI Kessels , I. Krajsova , M. Kukushkina , A. Lallas , P. Lorigan , J. Mangana , I. Marquez-Rodas , L. Mazilu , P. Mohr , M. Bylaite-Bucinskiene , J. Ocvirk , C. Garbe\",\"doi\":\"10.1016/j.ejca.2024.115124\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Advances in cancer treatments have significantly improved their effectiveness, yet access to first-line therapies remains limited. A 2017 survey revealed that over 25 % of metastatic melanoma patients in Europe lacked access to recommended therapies. To address this, the European Association of Dermato-Oncology and the European Melanoma Registry conducted a follow-up study on the registration and reimbursement of first-line treatments.A web-based survey using LimeSurvey was distributed to melanoma experts across 27 European countries from February to April 2022 and updated from February to April 2024. The questionnaire covered the percentage of patients receiving recommended treatments, as well as treatment authorization and reimbursement dates for systemic and adjuvant therapies.There has been significant improvement in the registration and reimbursement of BRAFi/MEKi, anti-PD1, and anti-PD1/anti-CTLA4 therapies, increasing from 48 %, 63 %, and 37 % in 2017 to 96 %, 96 %, and 78 % in 2024, respectively. Despite these gains, restrictions persist. Anti-PD1/anti-CTLA4 combination immunotherapy is still not available without restrictions in 48 % of the surveyed countries. The nivolumab/relatlimab combination is licensed only for PDL-1-negative melanoma and reimbursed in seven countries of Europe. Tebentafusp is reimbursed in 15 countries and talimogene laherpervec in 5. In 2024, adjuvant treatments for stage III melanoma are reimbursed in 22 countries for dabrafenib/trametinib and 24 of 27 for anti-PD1 antibodies. Pembrolizumab and nivolumab are reimbursed in 15 and 8 countries, respectively, for stage IIB/IIC disease.While there have been improvements in the reimbursement of metastatic melanoma treatments in Europe, challenges and discrepancies remain. Further efforts at European and global levels are needed to harmonize and enhance access to cancer medicines.</div></div>\",\"PeriodicalId\":11980,\"journal\":{\"name\":\"European Journal of Cancer\",\"volume\":\"216 \",\"pages\":\"Article 115124\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2025-02-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0959804924017313\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804924017313","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

癌症治疗的进步大大提高了其有效性，但获得一线治疗的机会仍然有限。2017年的一项调查显示，欧洲超过25%的转移性黑色素瘤患者无法获得推荐的治疗方法。为了解决这个问题，欧洲皮肤肿瘤协会和欧洲黑色素瘤登记处对一线治疗的注册和报销进行了随访研究。2022年2月至4月，一项基于网络的调查使用limessurvey向27个欧洲国家的黑色素瘤专家分发，并于2024年2月至4月更新。调查问卷涵盖了接受推荐治疗的患者百分比，以及系统和辅助治疗的治疗授权和报销日期。BRAFi/MEKi、抗pd1和抗pd1 /抗ctla4疗法的注册和报销有了显著改善，分别从2017年的48%、63%和37%增加到2024年的96%、96%和78%。尽管取得了这些进展，但限制依然存在。在接受调查的48%的国家中，抗pd1 /抗ctla4联合免疫疗法仍然没有限制。nivolumab/relatlimab组合仅被许可用于pdl -1阴性黑色素瘤，并在7个欧洲国家获得报销。Tebentafusp在15个国家报销，talimogene在5个国家报销。2024年，22个国家报销达非尼/曲美替尼的III期黑色素瘤辅助治疗，27个国家中的24个报销抗pd1抗体的辅助治疗。派姆单抗和纳武单抗分别在15个和8个国家用于IIB/IIC期疾病的报销。虽然欧洲转移性黑色素瘤治疗的报销有所改善，但挑战和差异仍然存在。需要在欧洲和全球各级作出进一步努力，以协调和加强获得癌症药物的机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

An update on access to novel treatment for metastatic melanoma in Europe — A 2024 survey of the European melanoma registry and the European association of dermato-oncology

Advances in cancer treatments have significantly improved their effectiveness, yet access to first-line therapies remains limited. A 2017 survey revealed that over 25 % of metastatic melanoma patients in Europe lacked access to recommended therapies. To address this, the European Association of Dermato-Oncology and the European Melanoma Registry conducted a follow-up study on the registration and reimbursement of first-line treatments.A web-based survey using LimeSurvey was distributed to melanoma experts across 27 European countries from February to April 2022 and updated from February to April 2024. The questionnaire covered the percentage of patients receiving recommended treatments, as well as treatment authorization and reimbursement dates for systemic and adjuvant therapies.There has been significant improvement in the registration and reimbursement of BRAFi/MEKi, anti-PD1, and anti-PD1/anti-CTLA4 therapies, increasing from 48 %, 63 %, and 37 % in 2017 to 96 %, 96 %, and 78 % in 2024, respectively. Despite these gains, restrictions persist. Anti-PD1/anti-CTLA4 combination immunotherapy is still not available without restrictions in 48 % of the surveyed countries. The nivolumab/relatlimab combination is licensed only for PDL-1-negative melanoma and reimbursed in seven countries of Europe. Tebentafusp is reimbursed in 15 countries and talimogene laherpervec in 5. In 2024, adjuvant treatments for stage III melanoma are reimbursed in 22 countries for dabrafenib/trametinib and 24 of 27 for anti-PD1 antibodies. Pembrolizumab and nivolumab are reimbursed in 15 and 8 countries, respectively, for stage IIB/IIC disease.While there have been improvements in the reimbursement of metastatic melanoma treatments in Europe, challenges and discrepancies remain. Further efforts at European and global levels are needed to harmonize and enhance access to cancer medicines.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Journal of Cancer 医学-肿瘤学

CiteScore

11.50

自引率

4.80%

发文量

953

审稿时长

23 days

期刊介绍： The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.